To discover potential future blockbuster stocks, take a look at the biotechnology sector. It can be challenging, but savvy investors might occasionally stumble upon highly promising biotech stocks that are still in their initial stages of growth.
Three experts from CORP-DEPO believe they’ve found promising stocks that could potentially become ‘monsters’. Here’s their reasoning behind choosing CRISPR Therapeutics (CRSP), Summit Therapeutics (SMMT), and Viking Therapeutics (VKTX).
A promising company in its early growth stage
I’m thrilled about the prospects of biotech giant, CRISPR Therapeutics, where I serve as part of the team. Currently valued at approximately $5 billion, this company has the potential to skyrocket in value in the long term. The gene editing market, while still in its infancy, holds immense promise for expansion. According to analysts from Grand View Research, this market is expected to surge at a rate of over 16% annually until 2030, reaching a staggering $25 billion. As a pioneer in this field, CRISPR Therapeutics is primed to capitalize on the imminent growth in healthcare related to gene editing.
In collaboration with Vertex Pharmaceuticals (NASDAQ: VRTX), the company has secured regulatory approval for a gene therapy treatment called Casgevy, effective for both sickle cell disease and transfusion-dependent beta-thalassemia. The two entities will split the profits from this treatment, with CRISPR receiving 40%. As Casgevy is still in its initial stages of growth, CRISPR is also actively pursuing the development of treatments for type 1 diabetes and cardiovascular disease. Although CRISPR operates at a loss today, its potential for future success appears promising.
Embarking on an exciting journey with CRISPR Therapeutics! With a promising pipeline and immense growth prospects, I firmly believe this could be a game-changer in the healthcare sector. The company’s robust financial standing, boasting over $1.9 billion in cash and marketable securities as of March, positions it perfectly to further its research and development endeavors. I can hardly wait to see what the future holds for CRISPR Therapeutics!
CRISPR can make for an excellent investment, but it’s also one you’ll need to be patient with.
Still plenty of upside left for this stock
Prosper Junior Bakiny (Summit Therapeutics): Few biotech firms have outperformed Summit Therapeutics over the previous three years. The company’s shares have skyrocketed by more than 2,000%, making early investors who continued their investments much richer. Here’s some encouraging news for potential future investors: There may still be a substantial increase in value for Summit Therapeutics. Despite not earning any revenue and being unprofitable, the company boasts one of the more promising product pipelines in the biotech industry.
Summit Therapeutics’ primary cancer treatment contender is the medication known as ivonescimab, which they obtained from Akeso Biopharma – a Chinese pharmaceutical company specializing in drug development.
The medication has undergone extensive testing in China and has received approval for specific uses there. One of ivonescimab’s most promising markets is non-small cell lung cancer (NSCLC). In a phase 3 study conducted in China, it was compared directly against the market leader and the world’s top-selling drug: Merck’s (NYSE: MRK) Keytruda. In this comparison, ivonescimab proved to be superior, resulting in a greater reduction in the risk of recurrence or death among NSCLC patients with high levels of the PD-L1 protein.
Summit Therapeutics is currently involved in clinical trials aimed at securing approval not just in the U.S., but also in other parts of the world. Over time, they are expected to pursue multiple approvals and label expansions due to the numerous clinical trials and indications for Akeso they have set in China. If all goes well with ivonescimab, it could become a major success story, bringing in substantial sales for many years. This makes investing in Summit Therapeutics a viable option even now. Should ivonescimab reach its full potential, Summit has the capability to outperform the market and solidify its position as a significant player within the biotech sector over the next 5 to 10 years.
Targeting two monster markets
Keith Speights (Viking Therapeutics) Highlights: The main focus for Viking Therapeutics lies with its experimental obesity drug, VK2735. Following the release of extremely promising Phase 2 trial results last year, they have now moved a subcutaneous formulation of this potential treatment into advanced clinical trials in the late stages.
As an observer, I’m sharing that the pharmaceutical company is conducting a separate Phase 2 trial for an oral variant of VK2735, with results anticipated towards the end of 2025. Excitingly, they also have plans to kick off a clinical study soon for a monthly maintenance version of subcutaneous VK2735.
According to Morgan Stanley’s research, the worldwide market for obesity drugs may grow to an astounding $150 billion by the year 2035. If VK2735 lives up to its potential, Viking could secure a substantial portion of that market.
The company, Viking, is not only focusing on obesity but also on metabolic-associated steatohepatitis (MASH), or nonalcoholic steatohepatitis (NASH), a type of chronic liver disease. In 2023, they reported promising findings from a phase 2 study of VK2809 for treating MASH/NASH. They are currently looking for a partner to proceed with advanced testing of VK2809, allowing them to concentrate fully on VK2735 at the moment. According to Grand View Research, the market for MASH/NASH could reach $33.8 billion by 2030, making it an attractive opportunity.
The unsuccessful clinical trial of VK2735 and/or the lack of a suitable partner for VK2809 might hinder Viking from achieving giant stock status. Nevertheless, I am optimistic about the company’s prospects. It is also possible that a larger pharmaceutical company may take over Viking.
Read More
- Gold Rate Forecast
- KPop Demon Hunters: Is Your Idol by Saja Boys Inspired by Real K-Pop Bands? Here’s What We Know
- Justin Bieber Teases New Album ‘SWAG’ with Tracklist Reveal
- Superman’s Record-Breaking $21M+ Thursday Box Office: Highest of 2025
- Ultraman Live Stage Show: Kaiju Battles and LED Effects Coming to America This Fall
- 📢 BrownDust2 X BiliBili World 2025 Special Coupon!
- 15 Best Sherlock Holmes Actors, Ranked from Worst to Best
- Dakota Johnson-Anne Hathaway’s Verity Release Date Out: Here’s When Colleen Hoover’s Movie Adaptation Will Hit the Screens
- Superman’s Rotten Tomatoes Score Blasts Past Expectations—Shocks Even the Harshest Critics
- Tokyo Game Show 2025 exhibitors announced
2025-07-21 07:14